274 related articles for article (PubMed ID: 25686830)
1. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
[TBL] [Abstract][Full Text] [Related]
2. Direct Binding of Cisplatin to p22phox, an Endoplasmic Reticulum (ER) Membrane Protein, Contributes to Cisplatin Resistance in Oral Squamous Cell Carcinoma (OSCC) Cells.
Hung CC; Li FA; Liang SS; Wang LF; Lin IL; Chiu CC; Lee CH; Chen JY
Molecules; 2020 Aug; 25(17):. PubMed ID: 32825798
[TBL] [Abstract][Full Text] [Related]
3. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
4. Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies.
Hung CC; Chien CY; Chu PY; Wu YJ; Lin CS; Huang CJ; Chan LP; Wang YY; Yuan SF; Hour TC; Chen JY
Head Neck; 2017 Aug; 39(8):1621-1630. PubMed ID: 28498554
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
6. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
[TBL] [Abstract][Full Text] [Related]
7. CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P; Shriwas O; Mohanty S; Ghosh A; Smita S; Kaushik SR; Arya R; Rath R; Das Majumdar SK; Muduly DK; Raghav SK; Nanda RK; Dash R
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434185
[TBL] [Abstract][Full Text] [Related]
8. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
[TBL] [Abstract][Full Text] [Related]
9. miR-654-5p Targets GRAP to Promote Proliferation, Metastasis, and Chemoresistance of Oral Squamous Cell Carcinoma Through Ras/MAPK Signaling.
Lu M; Wang C; Chen W; Mao C; Wang J
DNA Cell Biol; 2018 Apr; 37(4):381-388. PubMed ID: 29364705
[TBL] [Abstract][Full Text] [Related]
10. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
Chen L; Zhu Q; Lu L; Liu Y
Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
[TBL] [Abstract][Full Text] [Related]
11. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
12. Icaritin induces mitochondrial apoptosis by up-regulating miR-124 in human oral squamous cell carcinoma cells.
Jin L; Miao J; Liu Y; Li X; Jie Y; Niu Q; Han X
Biomed Pharmacother; 2017 Jan; 85():287-295. PubMed ID: 27889233
[TBL] [Abstract][Full Text] [Related]
13. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Li L; Liu HC; Wang C; Liu X; Hu FC; Xie N; Lü L; Chen X; Huang HZ
Biomed Res Int; 2016; 2016():5378567. PubMed ID: 27529071
[TBL] [Abstract][Full Text] [Related]
15. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
Zhu R; Mao Y; Xu X; Li Y; Zheng J
Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
[TBL] [Abstract][Full Text] [Related]
16. Silencing of GLUT-1 inhibits sensitization of oral cancer cells to cisplatin during hypoxia.
Shimanishi M; Ogi K; Sogabe Y; Kaneko T; Dehari H; Miyazaki A; Hiratsuka H
J Oral Pathol Med; 2013 May; 42(5):382-8. PubMed ID: 23227892
[TBL] [Abstract][Full Text] [Related]
17. Loss of Tumor Suppressor CYLD Expression Triggers Cisplatin Resistance in Oral Squamous Cell Carcinoma.
Suenaga N; Kuramitsu M; Komure K; Kanemaru A; Takano K; Ozeki K; Nishimura Y; Yoshida R; Nakayama H; Shinriki S; Saito H; Jono H
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31635163
[TBL] [Abstract][Full Text] [Related]
18. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
Alam M; Mishra R
Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
[TBL] [Abstract][Full Text] [Related]
19. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells.
Lee JC; Chung LC; Chen YJ; Feng TH; Chen WT; Juang HH
Cancer Lett; 2015 May; 360(2):310-8. PubMed ID: 25721086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
